Vivo Capital’s Cullinan Oncology CGEM Stock Holding History

Vivo Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-250,000	Closed	-$10.4M	–	62
2021 Q1	$10.4M	Buy	+250,000	New	+$10.1M	0.37%	40

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital's CGEM Position: Q2 2021 in Review

Vivo Capital sold out of Cullinan Oncology (CGEM) in Q2 2021, closing a stake of 250,000 shares — an estimated $10.4M sold.

Vivo Capital first reported a position in CGEM in Q1 2021 and held it in 1 quarter. The position peaked at $10.4M in Q1 2021. 71 funds tracked by Wall St. Rank hold CGEM as of Q2 2021.

Vivo Capital reported no remaining Cullinan Oncology position as of Q2 2021 after selling out during the quarter.
Vivo Capital sold 250,000 Cullinan Oncology shares in Q2 2021, an estimated $10.4M.
Vivo Capital first reported a position in Cullinan Oncology in Q1 2021 and held it in 1 quarter.
Vivo Capital's Cullinan Oncology position peaked at $10.4M in Q1 2021.
71 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2021.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.